Evidence map›Paper›PMID 37592407›Full record

ArticleJournal of internal medicine2024

UDCA treatment against COVID-19: Do we have enough clinical evidence for drug repurposing?

Luisa Ojeda-Fernández, Marta Baviera, Giulia Macaluso, Simone Schena, Mauro Tettamanti, Massimo Cartabia, Andreana Foresta, Pier Manuccio Manucci, Alessandro Nobili, Giuseppe Remuzzi and 1 more

Open access · hybridAbstract readLetterComment
PubMed Publisher
In one paragraph

Article in Journal of internal medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Luisa Ojeda-FernándezIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.ORCID 0000-0003-2920-1669
Marta BavieraIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Giulia MacalusoIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Simone SchenaIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Mauro TettamantiIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Massimo CartabiaIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Andreana ForestaIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Pier Manuccio ManucciFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and University of Milan, Milan, Italy.ORCID 0000-0002-1915-3897
Alessandro NobiliIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.ORCID 0000-0002-7813-0572
Giuseppe RemuzziIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Carla RoncaglioniIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Mario Negri Institute for Pharmacological Research · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Antiviral AgentsDrug RepositioningHumansSARS-CoV-2Antiviral Agents

Identifiers

PMID37592407
OpenAlexW4385968902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.